Skip to main content

Table 1 Baseline characteristics and demographics for patients enrolled in phase 1 (n = 43)

From: Phase 1/2 study of pacritinib, a next generation JAK2/FLT3 inhibitor, in myelofibrosis or other myeloid malignancies

  Pacritinib
100 mg 150 mg 200 mg 300 mg 400 mg 500 mg 600 mg All patientsa
n = 3 n = 6 n = 9 n = 6 n = 6 n = 7 n = 6 n = 43
Median age, years (range) 72.0 (59–78) 76.0 (66–86) 69.0 (63–76) 64.5 (50–77) 67.5 (52–83) 65.0 (49–77) 74.5 (53–76) 71.0 (49–86)
Male, n (%) 2 (66.7) 5 (83.3) 7 (77.8) 3 (50.0) 2 (33.3) 4 (57.1) 4 (66.7) 27 (62.8)
ECOG PS, n (%)
 0 0 2 (33.3) 5 (55.6) 4 (66.7%) 3 (50.0) 4 (57.1) 0 18 (41.9)
 1 2 (66.7) 2 (33.3) 4 (44.4) 1 (16.7) 2 (33.3) 2 (28.6) 5 (83.3) 18 (41.9)
 2 1 (33.3) 2 (33.3) 0 1 (16.7) 1 (16.7) 1 (14.3) 1 (16.7) 7 (16.3)
Median disease duration, months (range) 5.0 (4.1–6.7) 25.8 (8.6–174.4) 45.9 (2.3–410.2) 37.4 (8.5–341.8) 27.4 (5.1–132.2) 36.9 (10.0–182.9) 99.2 (13.7–196.9) 36.9 (2.3–410.2)
Current malignancy type, n (%)
 AML 0 3 (50.0) 0 0 3 (50.0) 0 1 (16.7) 7 (16.3)
   JAK2 mutationb, n/N (%) 1/3 (33.3) 2/3 (66.7) 1/1 (100) 4/7 (57.1)
 Myelofibrosis 3 (100.0) 3 (50.0) 9 (100.0) 6 (100.0) 3 (50.0) 7 (100.0) 5 (83.3) 36 (83.7)
   JAK2 mutationb, n/N (%) 2/3 (66.7) 2/3 (66.7) 8/9 (88.9) 5/6 (83.3) 3/3 (100) 5/7 (71.4) 4/5 (80.0) 29/36 (80.6)
  Median prior systemic therapies, n (range) 1.0 (0–4) 3.0 (2–4) 1.0 (0–4) 2.0 (1–4) 2.0 (1–4) 2.0 (0–4) 3.0 (1–4) 3.0 (0–4)
  Median time since last cancer treatment, months (range) 2.4 (1.5–3.2) 1.2 (0.1–6.3) 2.0 (0.5–39.6) 8.0 (0.5–37.1) 1.5 (0.5–2.4) 2.8 (0.7–27.1) 6.3 (0.6–21.7) 2.2 (0.1–39.6)
  1. a86% of patients were white
  2. bAll JAK2 mutations were V617F
  3. AML acute myeloid leukemia, ECOG PS Eastern Cooperative Oncology Group Performance Status, MDS myelodysplastic syndrome